Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VOSOL HC vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
Mild to moderate pain,Fever
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
90–95%, primarily to albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Otic: 80–90% (local absorption with minimal systemic).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dosage adjustment required for renal impairment.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dosage adjustment required for hepatic impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No known food interactions. Alcohol consumption is not restricted.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VOSOL HC vs ACEPHEN, answered by our medical review team.
VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VOSOL HC and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VOSOL HC and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.